Pharmafile Logo
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • - PMLiVE
  • Communiqué 53 Cover Image

Grifols

- PMLiVE

Grifols share results identifying early signs of Parkinson’s disease

Parkinson’s disease affects over six million people globally

- PMLiVE

Mission Therapeutics advances Parkinson’s disease candidate

The company also received a grant from the Michael J. Fox Foundation and Parkinson’s UK

- PMLiVE

Ventyx’s investigational NLRP3 inhibitor shows promise in Parkinson’s disease

Planning is currently underway for a placebo-controlled trial of the candidate

- PMLiVE

Roche to advance Parkinson’s disease candidate into phase 3 development

More than ten million people worldwide are living with the neurodegenerative disorder

- PMLiVE

UKDRI researchers to evaluate new blood test for neurodegenerative disease diagnosis

It is hoped that the test could be available for widespread UK use in the coming years

- PMLiVE

FDA grants RMAT designation to AskBio’s Parkinson’s gene therapy candidate

The progressive neurodegenerative disease affects more than ten million people worldwide

- PMLiVE

FDA approves Supernus Pharmaceuticals’ Onapgo to treat advanced Parkinson’s disease

The neurodegenerative disorder affects almost one million people in the US

- PMLiVE

AbbVie’s Parkinson’s disease candidate tavapadon shows promise in phase 3 trial

More than ten million people worldwide are living with the neurodegenerative disorder

- PMLiVE

AbbVie’s continuous Parkinson’s disease therapy Vyalev approved by FDA

More than ten million people worldwide are living with the neurological disorder

- PMLiVE

AbbVie shares promising late-stage results for Parkinson’s disease candidate tavapadon

Approximately 153,000 people in the UK are currently living with the neurodegenerative disorder

- PMLiVE

NICE recommends Grifols’ Tavlesse for chronic immune thrombocytopenia

Patients with chronic ITP may live with an increased risk of severe bleeding events

- PMLiVE

Michael J Fox Foundation awards $4.9m grant to Muna Therapeutics

The grant will support the development of the company’s disease modifying therapy for Parkinson's disease

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links